UNSPSC 51282128: Faropenem daloxate

This classification denotes a beta-lactam antibiotic with the molecular formula C17H19NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OK523O4FU, chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5r,6s), but more generally known as faropenem daloxate, which bears US NIH Compound Identifier 6918218.

European Medicines Agency schedules faropenem daloxate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07512MIG. Most nations, for tariff purposes, schedule faropenem daloxate under HS 29419000. SMILES: CC1C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4.

UNSPSC 51282128 Faropenem daloxate, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The code's abstract designation points to a specific pharmaceutical compound, yet recent opportunities tagged under this code predominantly solicit naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs—none of which involve faropenem daloxate. The mismatch between the code name and the actual work being solicited suggests either classification inconsistency in the source data or that faropenem daloxate itself does not drive meaningful state and local procurement volume currently. When state and local buyers do solicit pharmaceutical products under pharmacy-related codes, they acquire finished drugs, medical consumables, and pharmacy benefit management services through competitive sealed bidding, RFPs, and cooperative purchasing agreements rather than raw active pharmaceutical ingredients.

The issuing bodies soliciting pharmaceutical and health-related supplies include county health departments (Seminole County, Florida), city fire and rescue divisions (City of Tampa), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local participants across multiple jurisdictions including Oregon). Recent opportunities span Florida, Texas, and Minnesota, with Texas and Minnesota showing formal RFP activity. Representative procurements include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, 1,900 units of naloxone and 800 deactivation systems annually), the City of Tampa's ITB for medical and first aid supplies for fire rescue operations (due March 13, 2026, 169 line items, $700,000 estimated value, sheltered for certified Small Local Business Enterprises with a 5 percent bid discount), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, serving state and local facilities in Minnesota and Oregon through three authorized wholesalers). The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) represents exploratory procurement strategy rather than a finalized opportunity. No recent opportunities directly solicit faropenem daloxate.